Background: HIV-infected individuals are reported to have higher levels of neurocognitive impairment than HIV-negative controls. We examined the association between independent HIV-1 replication in the CNS and neurocognitive impairment.
Methods: We used cerebrospinal fluid (CSF) and blood plasma samples from 40 subjects off antiretroviral therapy (ART) to characterize viral populations in the CNS and blood. Subjects were enrolled in 1 of 4 cohorts. Two cohorts enrolled subjects based on neurological symptoms and two enrolled subjects based on CD4 count and viral load. All subjects had neurocognitive assessments. cDNA was generated from viral RNA and partial env genes were amplified and sequenced by Illumina deep sequencing with Primer ID to quantify the number of templates examined (Fig. 1A); and/or full length env genes were amplified and sequenced by single genome amplification (SGA)(Fig. 1B). Pseudotyped viruses were generated from cloned, full-length env genes and used in entry assays to determine whether Env proteins were well-adapted to entering cells expressing low levels of CD4 (i.e. macrophage-tropic; Fig 1C).
Results: Based on formal neurocognitive assessments, subjects were classified into three groups with increasing levels of neurocognitive impairment: 1) normal (N=7), 2) mild neurocognitive disorder or asymptomatic neurocognitive impairment (N=10), and 3) HIV-associated dementia (N=23). The observation of genetically distinct, viral lineages in the CSF was evidence of ongoing replication in that compartment, and these lineages were considered compartmentalized (Fig. 1A and 1B). Increasing neurocognitive impairment was positively associated with compartmentalization (exact trend test, p=0.04). For 71% of subjects with compartmentalized HIV-1 in their CSF, this virus was also macrophage-tropic, and thus compartmentalization was significantly associated with macrophage tropism (fisher’s exact test, p= 0.001).
Conclusions: HIV-1 replication in the CNS is strongly associated with neurocognitive impairment and the majority of subjects with evidence of ongoing HIV-1 replication in the CNS have macrophage-tropic HIV-1 in that compartment. These results suggest that there may be a causal relationship between HIV-1 replication in macrophage-lineage cells in the CNS and neurocognitive symptoms in HIV-infected subjects off therapy. Antiretroviral therapy that fully suppresses viral replication in the CNS, particularly in macrophages, may be more likely to improve neurocognitive performance.